Cbl-b-IN-2

• UNSPSC Description:

  Cbl-b-IN-2 (Example 8) is an orally bioavailable compound, can inhibit the E3 enzyme Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) in the ubiquitin proteasome pathway. Cbl-b-IN-2 can be used to modulate the immune system and diseases amenable to immune system modulation. Cbl-b-IN-2 (Example 8) also may be administered to an individual with cancer, either alone or as part of a combination, with one or more of an immune checkpoint inhibitor, an anti-neoplastic agent, and radiation agent[1].

• Target Antigen:

  E3 Ligase Ligand-Linker Conjugates

• Type:

  Reference compound

• Related Pathways:

  PROTAC

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cbl-b-in-2.html

• Solubility:

  DMSO : 140 mg/mL (ultrasonic)

• Smiles:

  O=C1N(C2=CC=CC(C3(CC4=NN=CN4C)COC3)=C2)CC5=C1C=C(CN6C[C@@H](C)C(F)(F)CC6)C=C5C(F)(F)F

• Molecular Weight:

  575.57

• References & Citations:

  [1]Arthur T. Sands, et al. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus. Patent WO 2020210508A1.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2503325-21-9